---
type: "Symbol"
title: "Haisen Pharm (001367.SZ) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/001367.SZ/topics.md"
symbol: "001367.SZ"
parent: "https://longbridge.com/en/quote/001367.SZ.md"
count: 1
datetime: "2026-03-16T00:19:59.860Z"
locales:
  - [en](https://longbridge.com/en/quote/001367.SZ/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/001367.SZ/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/001367.SZ/topics.md)
---

# Haisen Pharm (001367.SZ) — Community Discussions

### [A 10.68% year-on-year increase in net profit is just the surface. Is Haisco Pharmaceutical Group actually moving forward under pressure?](https://longbridge.com/en/topics/24634754.md)

- Author: [医药研究社](https://longbridge.com/en/profiles/15545088.md)
- Datetime: 2024-10-22T06:46:08.000Z
- Comments: 0
- Haisco Pharmaceutical Group adopts a "multi-legged approach", with soaring revenue on one hand and slowing profit growth on the other. Source｜Pharmaceutical Research Society Since its IPO in A

## References

- [Haisen Pharm (001367.SZ)](https://longbridge.com/en/quote/001367.SZ.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/001367.SZ/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/001367.SZ/topics.md)